Systemic sclerosis & Raynaud's
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model
Authors' conclusion
The DU-VASC model, with good calibration and discrimination ability, revealed that PI treatment was the most important therapy-related predictor associated with reduced DU occurrence.
Study context
- Population
- Patients with SSc in the EUSTAR registry487 with digital ulcers (DUs)
- Participants
- 3,710 patients
- Outcome
- Prediction of DUs (DU-VASC model performance: C-statistic and calibration)
Methodological detailsregistry-based (EUSTAR), one time point assessed, three derivation/validation cohort sets, logistic regression, independent temporal validation
- Registry-based (EUSTAR)
- One time point assessed
- Three derivation/validation cohort sets
- Logistic regression
- Independent temporal validation
Performance
As reported in the abstract
DU-VASC model (27 predictors) discrimination, C-statistic
C-statistic, derivation cohort
81.1%
95% CI 78.9%, 83.4%
C-statistic, independent temporal validation cohort
82.3%
95% CI 779.3%, 85.3%
Further findings
- Exposure to platelet inhibitors (PIs) associated with absence of DUs; most important therapeutic predictor
- Lower mRSS, anti-Scl-70 negativity and normal CRP associated with absence of DUs
- Exposure to phosphodiesterase-5 inhibitor, prostacyclin analogues or endothelin receptor antagonists seemed associated with occurrence of DUs
- Previous DUs the most impactful predictor of DUs
Original publication
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology (Oxford). Published 29 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →